Relay Therapeutics
Iain Martin brings to Relay more than 30 years of experience in pharmaceutical drug metabolism and pharmacokinetics (DMPK) across therapeutic areas, including oncology and neuroscience. Prior to joining Relay, he was executive director within the department of pharmacokinetics, pharmacodynamics and drug metabolism at Merck, where he led groups responsible for DMPK support of small molecule and peptide programs across the company. Prior to Merck, Iain held roles of increasing responsibility at The Upjohn Company, AstraZeneca, Organon and Schering Plough.
Iain holds a Ph.D. in drug metabolism and a B.S. in biochemistry from the University of Surrey (UK).
Relay Therapeutics
1 followers
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology.